Investors who own more than 5% of a class must file a Schedule 13D or 13G. The latest filing for each security since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Xilio Therapeutics, Inc.
13G/A
XLO · 98422T209
|
9.5% |
8/14/2026
Event 6/30/2026
|
|||
| StemPoint Capital LP | 9.5% | ||||
| StemPoint Capital Management GP LLC | 9.5% | ||||
| Michelle Ross | 9.5% | ||||
|
Surrozen, Inc.
13G
SRZN · 86889P208
|
5.0% |
8/14/2026
Event 6/30/2026
|
|||
| StemPoint Capital LP | 5.0% | ||||
| StemPoint Capital Management GP LLC | 5.0% | ||||
| Michelle Ross | 5.0% | ||||
|
Faeth Therapeutics, Inc.
13G/A
FTH · 81728A207
|
0% |
8/14/2026
Event 6/30/2026
|
|||
| StemPoint Capital LP | 0% | ||||
| StemPoint Capital Management GP LLC | 0% | ||||
| Michelle Ross | 0% | ||||
|
Cellectar Biosciences, Inc.
13G
CLRB · 15117F880
|
9.9% |
8/14/2026
Event 6/30/2026
|
|||
| StemPoint Capital LP | 9.9% | ||||
| StemPoint Capital Management GP LLC | 9.9% | ||||
| Michelle Ross | 9.9% | ||||
|
Vistagen Therapeutics, Inc.
13G/A
VTGN · 92840H400
|
1.5% |
2/17/2026
Event 12/31/2025
|
|||
| StemPoint Capital LP | 1.5% | ||||
| StemPoint Capital Management GP LLC | 1.5% | ||||
| Michelle Ross | 1.5% | ||||
|
Xilio Therapeutics, Inc.
13G/A
XLO · 98422T100
|
8.4% |
2/17/2026
Event 12/31/2025
|
|||
| StemPoint Capital LP | 8.4% | ||||
| StemPoint Capital Management GP LLC | 8.4% | ||||
| Michelle Ross | 8.4% | ||||